
Galapagos NV GLPG
Quartalsbericht 2025-Q4
hinzugefügt 06.05.2026
Galapagos NV EV/EBITDA 2011-2026 | GLPG
EV/EBITDA Jährlich Galapagos NV
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.67 | -19.2 | -78.8 | -69 | -26.5 | -26.8 | -4.83 | -165 | -42 | 1.04 K | -16.3 | -13.7 | -68.5 | -746 | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.04 K | -746 | -16.4 |
EV/EBITDA anderer Aktien in der Pharmaeinzelhändler
| Name | EV/EBITDA | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-0.271 | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-0.984 | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
-0.164 | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
-1.86 | $ 1.66 | 1.22 % | $ 194 M | ||
|
I-Mab
IMAB
|
595 | - | - | $ 866 M | ||
|
Celldex Therapeutics
CLDX
|
-7.28 | $ 31.65 | 2.59 % | $ 2.1 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B | ||
|
BioNTech SE
BNTX
|
-12.2 | $ 93.0 | 0.81 % | $ 22.5 B | ||
|
CRISPR Therapeutics AG
CRSP
|
13.1 | $ 53.53 | 3.76 % | $ 4.81 B | ||
|
AstraZeneca PLC
AZN
|
3.06 | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
0.0485 | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
8.55 | - | 0.74 % | $ 768 M | ||
|
Compugen Ltd.
CGEN
|
3.32 | $ 2.76 | 4.15 % | $ 258 M | ||
|
Abcam plc
ABCM
|
-513 | - | - | $ 4.9 B | ||
|
Galera Therapeutics
GRTX
|
2.25 | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
0.204 | - | -18.52 % | $ 27.3 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-29.5 | $ 0.78 | 14.33 % | $ 35.6 M | ||
|
Esperion Therapeutics
ESPR
|
19.2 | $ 3.13 | 0.32 % | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
187 | $ 32.4 | 3.55 % | $ 872 M | ||
|
Affimed N.V.
AFMD
|
0.361 | - | -34.95 % | $ 21.5 M | ||
|
Forte Biosciences
FBRX
|
-3.97 | $ 21.47 | -2.14 % | $ 278 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-0.186 | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
0.0447 | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
-1.29 | - | -7.31 % | $ 87 M | ||
|
Galectin Therapeutics
GALT
|
-15.3 | $ 2.7 | -3.23 % | $ 173 M | ||
|
Generation Bio Co.
GBIO
|
-0.5 | - | - | $ 344 M | ||
|
IMV
IMV
|
-3.88 | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
-10.5 | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.27 | - | 0.23 % | $ 488 M | ||
|
Grifols, S.A.
GRFS
|
13.7 | $ 8.05 | 0.5 % | $ 5.47 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-0.142 | - | - | $ 7.46 M | ||
|
Hutchison China MediTech Limited
HCM
|
-481 | $ 11.72 | -0.26 % | $ 10.1 B | ||
|
Heron Therapeutics
HRTX
|
-1.84 K | $ 0.91 | 3.0 % | $ 152 M | ||
|
ImmuCell Corporation
ICCC
|
15.7 | $ 10.63 | 1.24 % | $ 95.9 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
0.257 | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
-2.56 | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
2.07 | - | - | $ 3.37 B | ||
|
Anika Therapeutics
ANIK
|
-27.5 | $ 14.81 | -0.54 % | $ 212 M | ||
|
Advaxis
ADXS
|
0.084 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-0.963 | - | 5.93 % | $ 314 M | ||
|
Ionis Pharmaceuticals
IONS
|
-363 | $ 76.49 | 0.55 % | $ 12.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.268 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M |